Chandrasekhar Bal

Employment

• All-India Institute of Medical Sciences Professor & Head
  2013 - Present

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (23)

• Long-term outcomes in medullary thyroid cancer patients treated with [177Lu]Lu-DOTAGA.FAPi dimer therapy
  EJNMMI Research 2026 DOI: 10.1186/s13550-026-01474-0
  +Save
• Advances With 225Ac-DOTATATE Targeted Alpha Therapy in Somatostatin Receptor Positive Neuroendocrine Tumors
  Seminars in Nuclear Medicine 2025 DOI: 10.1053/j.semnuclmed.2025.06.008
  +Save
• Low‐Dose Versus High‐Dose Lenvatinib in Radioiodine Refractory Differentiated Thyroid Cancer—A Real‐World Safety and Efficacy Analysis
  Clinical Endocrinology 2025 DOI: 10.1111/cen.15214
  +Save
• Optimal Cumulative I-131 Activity in Metastatic Differentiated Thyroid Cancer: Balancing Efficacy and Adverse Events
  The Journal of Clinical Endocrinology & Metabolism 2024 DOI: 10.1210/clinem/dgae024
  +Save
• [177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study
  European Journal of Nuclear Medicine and Molecular Imaging 2024 DOI: 10.1007/s00259-024-06677-y
  +Save
• Impact of radioiodine therapy on recurrence and survival outcomes in intermediate‐risk papillary thyroid carcinoma —A systematic review and meta‐analysis
  Clinical Endocrinology 2024 DOI: 10.1111/cen.15001
  +Save
• Therapeutic potential of [177Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment
  European Journal of Nuclear Medicine and Molecular Imaging 2024 DOI: 10.1007/s00259-023-06482-z
  +Save
• Dynamic Risk Stratification for Predicting Long-term Outcomes in Pediatric Differentiated Thyroid Cancers
  The Journal of Clinical Endocrinology & Metabolism 2023 DOI: 10.1210/clinem/dgac731
  +Save
• Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study
  European Journal of Nuclear Medicine and Molecular Imaging 2023 DOI: 10.1007/s00259-023-06340-y
  +Save
• Radioiodine versus no radioiodine outcomes in low‐risk differentiated thyroid cancers: A propensity‐score matched analysis
  Clinical Endocrinology 2023 DOI: 10.1111/cen.14950
  +Save